Caterpillar Inc vs GeneDx Holdings Corp — how do they compare? Caterpillar Inc trades at $867.14 (market cap $387.68B), while GeneDx Holdings Corp trades at $82.5 (market cap $2.44B). The key difference: Caterpillar Inc is far larger — about 158.9× GeneDx Holdings Corp's market cap, and Caterpillar Inc pays a 0.77% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| CAT | WGS | |
|---|---|---|
Market Cap | $387.68B | $2.44B |
Sector | Industrials | Technology |
52-Week High | $1.06K | $167.51 |
52-Week Low | $407.79 | $34.51 |
Enterprise Value | $426.11B | $2.48B |
Dividend Yield | 0.77% | — |
Signals from Pluang's Aura AI — not financial advice
Caterpillar (CAT) trades at $837.58, down 0.55% on the day, with a bearish technical signal but strong fundamental performance. Recent quarters have consistently beaten EPS estimates, with Q2 2026 EPS of $8.17 surpassing the $6.22 expectation. Revenue growth is supported by AI data center demand, contributing to a robust $67.59B in 2025 revenue. The stock is near key support at $831, with resistance at $850.
Outlook remains positive due to strong earnings momentum and AI-driven infrastructure demand, though elevated valuation ratios (P/E of 36.32) pose a risk. Analyst consensus is bullish with a $1,010 price target, but investors should monitor macroeconomic pressures and competitive threats. The dividend history and cash flow stability add defensive appeal.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Caterpillar Inc. designs, manufactures, and markets construction, mining, and forestry machinery. The Company also manufactures engines and other related parts for its equipment, and offers financing and insurance. Caterpillar distributes its products through a worldwide organization of dealers.
Read more on CAT →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →